DDrare: Database of Drug Development for Rare Diseases

226. 間質性膀胱炎（ハンナ型）
［臨床試験数：133，薬物数：151（DrugBank：46），標的遺伝子数：48，標的パスウェイ数：137］

Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2% sodium chondroitin sulfate; 5% lidocaine/5 mg/ml 0.02% estradiol compound cream; AGN 203818; AQX-1125; AQX-1125 100 mg; AQX-1125 200 mg; ASP3652; ASP6294; Adalimumab; Alkalinized Lidocaine-Heparin; Amitriptyline; BOTOX 200U in normal saline; Bladder Instillations; Bladder instillation WITH triamcinolone acetonide; Bladder instillation WITHOUT triamcinolone acetonide; Bladder instillation with heparin/ lidocaine; Botox; Botulinum toxin A; Buckwheat; Bupivacaine; CICLOSPORIN; Cannabidiol; Cannabidiol vaginal suppository; Capsaicin; Certolizumab pegol; Chondroitin sulfate; Ciclosporin; Ciklosporin; Combination Product: Hyperbaric Oxygen Therapy-; Cyclosporine; DMSO; DMSO cocktail; Device: Intermittent Exposure to Oxygen via Oro-Nasal Mask; Device: interferential current; Dexmedetomidine; Dimethyl sulfoxide; ERB-041; Estradiol; Fospropofol; Fospropofol (Lusedra®) 10; Fospropofol (Lusedra®) 12; Fospropofol (Lusedra®) 6.5; Fremanezumab; Gefapixant; Glycine; Gralise; Heparin; Heparin & Alkalinized Lidocaine Bladder Instillation; Hyaluronic Acid and Chondroitin Sulfate; Hyaluronic acid; Hyaluronic acid/chondroitin sulfate; Hydrogen; IC Cocktail; IPD® (Japanese tradename); IPD® (suplatast tosilate); Intravesical onabotulinumtoxinA injection; JNJ-42160443; KRP-116D; Ketorolac; Ketorolac Tromethamine; LP-08 20mg; LP-08 80mg; LiRIS 400 mg; LiRIS low dose and LiRIS high dose; LiRIS®; LiRIS® 400 mg; Lidocaine; Lidocaine Releasing Intravesical System - LiRIS®; Liposome encapsulated BoNT-A; Liposomes; Low-dose naltrexone; MMF; MN-001; MN-001 BID; MR-MC-01; Metoprolol; Metoprolol Tartrate Oral Tablet; Mirabegron; Mycofenolate Mofetil (MMF); Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; NALOXONE HYDROCHLORIDE; Naloxone; Naltrexone; Normal Saline; Normal saline; Normal saline instillation; Nortriptyline; OXN 10/5 mg PR; OXN 20/10 mg PR; OXN 5/2.5 mg PR; OXYCODONE HYDROCHLORIDE; Omalizumab; Onabotulinum Toxin A; Onabotulinumtoxin A; OnabotulinumtoxinA; Other: Hyperbaric Oxygen Therapy; Other: Normal Saline; Other: Saline as a nasal spray; Other: inactive drug; Other: normal saline; Oxycodone; Oxycodone naloxone prolonged release tablets; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Oxygen; Oxytocin; PD 0299685; PD 0299685 at 15mg BID; PD 0299685 at 30mg BID; PD-0299685; PF-04383119; Pentosan polysulfate; Pentosan polysulfate sodium 100 mg; Placebo; Platelet enriched plasma; Platelet-Rich Plasma; Procedure: Pelvic Floor Physical Therapy; Procedure: Sham Cystoscopy Procedure; Procedure: Urodynamic study; Procedure: injections on posterior bladder wall excluding the trigone; Procedure: injections upper aspect of trigone of urinary bladder; Prograf; Propiverine; Propiverine Hydrochloride; RIMSO 50; RN624, RI624; Rimso 50; SANDIMMUN; SI-722; Sandimmun Neoral; Sildenafil; Sulfate; Suplatast tosilate; TACROLIMUS; TTI-1612; Tacrolimus; Tanezumab; Targinact 10 mg/5 mg prolonged-release tablets; Targinact 20mg/10 mg prolonged-release tablets; Targinact 5mg/2.5 mg prolonged-release tablets; Tramadol; Triamcinolone; Tromethamine; URG101; Water; YM672; YM672 (IPD®)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03076762 (ClinicalTrials.gov)	March 2015	1/3/2017	Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis	Comparative Study of the Efficacy and Safety Between Suburothelial and Trigonal Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Randomized, Clinical Trial	Bladder Pain Syndrome	Drug: intravesical onabotulinumtoxinA injection	Buddhist Tzu Chi General Hospital	NULL	Recruiting	18 Years	N/A	All	60	Phase 2	Taiwan
2	NCT02247557 (ClinicalTrials.gov)	September 2014	15/9/2014	Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis	Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis — a Randomized, Double-blind, Placebo-controlled, Prospective Study	Interstitial Cystitis	Drug: Liposome encapsulated BoNT-A;Drug: BOTOX 200U in normal saline;Drug: Normal saline	Buddhist Tzu Chi General Hospital	NULL	Completed	20 Years	80 Years	All	90	Phase 2	Taiwan
3	NCT01969773 (ClinicalTrials.gov)	December 2012	22/10/2013	Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment	Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial	Interstitial Cystitis	Drug: Botulinum toxin A;Drug: Normal saline instillation	Buddhist Tzu Chi General Hospital	NULL	Completed	20 Years	85 Years	All	60	Phase 2	Taiwan
4	EUCTR2007-005164-27-NL (EUCTR)	22/02/2008	17/10/2007	Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/Interstitial Cystitis	Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/Interstitial Cystitis	Interstitial Cystitis (IC) is a syndrome characterized by bladder pain associated with urgency, frequency, nocturia, dysuria and sterile urine. The patho-physiology remains largely unclear. No universally, effective, treatment exists. Botulinum toxin-A (BTX-A) inhibits the release of acetylcholine at the presynaptic cholinergic junction resulting in temporally muscle relaxation and bladder desensitisation. We explore the effects of intravesical injections with BTX-A in the treatment of IC.	Trade Name: Botox	research office urology VUmc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12		Netherlands
5	NCT00194610 (ClinicalTrials.gov)	May 2004	13/9/2005	Botox as a Treatment for Interstitial Cystitis in Women	Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial	Painful Bladder Syndrome;Interstitial Cystitis	Drug: Botox;Other: normal saline	University of Washington	Paul G. Allen Family Foundation	Completed	18 Years	N/A	Female	20	Phase 4	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03076762
(ClinicalTrials.gov)

March 2015

1/3/2017

Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis

Comparative Study of the Efficacy and Safety Between Suburothelial and Trigonal Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Randomized, Clinical Trial

Bladder Pain Syndrome

Drug: intravesical onabotulinumtoxinA injection

Buddhist Tzu Chi General Hospital

NULL

Recruiting

18 Years

N/A

All

Phase 2

Taiwan

NCT02247557
(ClinicalTrials.gov)

September 2014

15/9/2014

Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis

Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis — a Randomized, Double-blind, Placebo-controlled, Prospective Study

Interstitial Cystitis

Drug: Liposome encapsulated BoNT-A;Drug: BOTOX 200U in normal saline;Drug: Normal saline

Buddhist Tzu Chi General Hospital

NULL

Completed

20 Years

80 Years

All

Phase 2

Taiwan

NCT01969773
(ClinicalTrials.gov)

December 2012

22/10/2013

Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment

Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

Interstitial Cystitis

Drug: Botulinum toxin A;Drug: Normal saline instillation

Buddhist Tzu Chi General Hospital

NULL

Completed

20 Years

85 Years

All

Phase 2

Taiwan

EUCTR2007-005164-27-NL
(EUCTR)

22/02/2008

17/10/2007

Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/Interstitial Cystitis

Interstitial Cystitis (IC) is a syndrome characterized by bladder pain associated with urgency, frequency, nocturia, dysuria and sterile urine. The patho-physiology remains largely unclear. No universally, effective, treatment exists. Botulinum toxin-A (BTX-A) inhibits the release of acetylcholine at the presynaptic cholinergic junction resulting in temporally muscle relaxation and bladder desensitisation. We explore the effects of intravesical injections with BTX-A in the treatment of IC.

Trade Name: Botox

research office urology VUmc

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Netherlands

NCT00194610
(ClinicalTrials.gov)

May 2004

13/9/2005

Botox as a Treatment for Interstitial Cystitis in Women

Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial

Painful Bladder Syndrome;Interstitial Cystitis

Drug: Botox;Other: normal saline

University of Washington

Paul G. Allen Family Foundation

Completed

18 Years

N/A

Female

Phase 4

United States